TCR2 Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.(i)
  • TCR2 Therapeutics received $125.0M in venture funding in March 2018.
  • TCR2 Therapeutics's estimated revenue per employee is $42,009
  • TCR2 Therapeutics's total funding is $173.3M.
  • TCR2 Therapeutics's current valuation is $153.3M. (January 2022)

Employee Data

  • TCR2 Therapeutics has 107 Employees.(i)
  • TCR2 Therapeutics grew their employee count by -29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





TCR2 Therapeutics News

2022-04-17 - Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ ...

Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.74 Per Share. Posted by admin on Apr 20th, 2022.

2022-03-30 - TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Benzinga

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from...

2022-03-30 - TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC ...

TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...

2019-09-12 - TCR2 Therapeutics, NCI Team Up to Test TC-210 ...

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...

2019-08-31 - TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?

TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

TCR2 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-12-12$44.5MAMPM CapitalArticle
2018-03-22$125.0MB6 Dimensions CapitalArticle